MobileODT and partners to launch first wide-scale deployment of AI screening for Cervical Cancer
Chennai, India – January 7, 2019 – MobileODT, developer of the Enhanced Visual Assessment (EVA) System, will partner with Genworks and Apollo Hospitals to deliver its FDA-cleared smart mobile colposcope. The project will perform the first large-scale pilot of Augmented Intelligence (AI) for use in the screening of cervical cancer.
This deployment will give healthcare professionals cutting edge, yet low-cost mobile technology to reach millions of women across India who previously had limited access to life-saving cervical exams.
Over 432 million women in India are at risk of developing cervical cancer, yet only 3.1% receive screening. Lack of equipment, qualified colposcopists, and socioeconomic conditions contribute to low screening numbers. When women do get screened with HPV testing or a Pap Smear, up to 80% with positive results do not return for treatment. Such loss of follow up can have deadly results for a highly treatable form of cancer when caught early.
With the advent of AI capabilities, remote collaboration, and improved workflow via the mobile EVA System, more women in India will have access to cervical cancer screening through non-expert analysis at the point of care. The EVA System is currently in use in 29 countries and over 50 US health systems.
The clinical study to be conducted at Apollo Hospital Centres throughout India will improve the AI algorithm used in cervical cancer detection by comparing cytologic cotesting to the algorithm performance, using biopsy as ground truth. This represents the first wide-scale validation of the algorithm, screening up to 250 women each day.
The capabilities of using the EVA System along with the algorithm will greatly improve the lives of women across India by providing on the spot diagnosis and improved patient tracking through the secure digital platform. A previous pilot conducted in six Apollo Hospital Centers to assess the value of the EVA System on improving patient and provider experience found that the EVA System helped early detection of cervical cancer for almost three times as many women compared to those who were identified positive with Pap smear. The study was coordinated by Apollo Research and Innovations (ARI), the research division of Apollo Hospitals Group.
About MobileODT
MobileODT is reimagining medical visualization technology to enhance women’s health. Combining advanced imaging, data and software applications, Mobile ODT is saving lives by enabling early cancer detection.
For further information, please contact:
Yael Misrahi – yaelmisrahi@mobileodt.com
